Mammalian Neuraminidase-1 is a Critical Regulator of Platelet-derived Thromboxane A2 (TXA2) T-cell Immunosuppression to Promote Tumor Progression and Metastasis

Technical Summary: Mammalian Neuraminidase-1 as a Regulator of TXA2-Mediated T-cell Immunosuppression

Problem Statement
While clinical data demonstrates that both aspirin and celecoxib, when combined with chemotherapy, significantly reduce disease recurrence and improve survival in colorectal cancer patients harboring PIK3CA mutations, the underlying biological mechanisms remain incompletely understood. A known pathway involves platelet-derived thromboxane A2 (TXA2), which suppresses T-cell activity via the guanine exchange factor ARHGEF1; aspirin inhibits this process by blocking TXA2 production through cyclooxygenase-1 (COX-1) inhibition. However, a critical discrepancy exists: celecoxib, a selective COX-2 inhibitor, does not inhibit platelet TXA2 production yet exhibits clinical efficacy comparable to aspirin. This suggests the existence of an alternative or parallel mechanism by which celecoxib preserves T-cell functionality and cancer immunity despite not blocking TXA2 synthesis.

Methodology and Key Findings
The authors investigated the molecular mechanisms linking TXA2 signaling to T-cell suppression to resolve the paradox of celecoxib's efficacy. The study identified mammalian neuraminidase 1 (NEU1) as a critical regulator in this pathway. The research established that:

• NEU1 is involved in the activation and downstream signaling of the TXA2 receptor (TP) on T cells in response to TXA2.
• Both aspirin and celecoxib significantly inhibit TXA2-induced NEU1 activity.
• The inhibition of NEU1 by these drugs leads to a reduction in ARHGEF1 expression, thereby preserving T-cell functionality.

Key Contributions
The primary contribution of this work is the identification of NEU1 as a downstream effector of TXA2 signaling on T cells. The study elucidates that NEU1 mediates the immunosuppressive effects of TXA2 by facilitating TP receptor activation and subsequent ARHGEF1 upregulation. Crucially, the findings demonstrate that both aspirin and celecoxib converge on the inhibition of NEU1 activity. This provides a mechanistic explanation for the observed clinical equivalence between the two drugs: while aspirin acts upstream by preventing TXA2 synthesis, celecoxib (and aspirin) acts downstream by inhibiting NEU1 activity, thereby blocking the TXA2-TP-ARHGEF1 axis regardless of TXA2 levels.

Significance and Claims
The paper posits that the regulation of the TP receptor by NEU1 explains the comparable clinical efficacy of aspirin and celecoxib in PIK3CA-mutant colorectal cancer, despite their distinct effects on TXA2 synthesis. By defining NEU1 as a pivotal node in the TXA2-mediated T-cell immunosuppression pathway, the authors suggest that targeting NEU1 represents a novel therapeutic strategy. Specifically, inhibiting NEU1 could promote tumor progression control and prevent metastasis by preserving functional T-cell responses against cancer, offering a potential avenue for therapeutic intervention beyond traditional COX inhibition.